Get the Daily Brief
Latest Biotech News
Emerging Therapeutics Target Immune and Inflammatory Disorders
New treatments show progress against autoimmune and inflammatory conditions. Apogee Therapeutics' anti-IL-13 antibody demonstrated significant efficacy with a more convenient dosing schedule in...
Innovations in Gene Editing and RNA Therapeutics
Breakthroughs in gene editing and RNA-based therapies continue to shape biotech innovation. New software simplifies precision CRISPR genome editing, making it accessible to a broader research...
Biotech Industry Faces Funding Trends and Strategic Shifts
Biopharma financing totaled $28.7 billion in the first half of 2025, marking a 59% decline from the previous year, aligning instead with levels from 2022 and 2023. Med-tech funding, however,...
Microbiome Research Links Infant Gut Deficiency to Disease Risk
The My Baby Biome project, involving 412 infants across the US, found that over 75% of babies exhibit deficiencies in key gut bacteria associated with healthy microbiomes. These deficits correlate...
Novartis launches first malaria drug for newborns after Swiss greenlight
Novartis has secured regulatory approval in Switzerland for Coartem Baby, the first malaria treatment designed for newborns and young infants, addressing a major treatment gap. The company plans...
FDA grants accelerated nod to Dizal's lung cancer therapy ahead of PDUFA
Ahead of its scheduled PDUFA date, the FDA granted accelerated approval to Dizal Pharmaceutical's sunvozertinib (Zegfrovy) for adults with locally advanced or metastatic non-small-cell lung cancer...
Cogent Biosciences advances mastocytosis drug with positive Phase 3 results
Cogent Biosciences announced positive top-line data from its Phase 3 Summit trial evaluating bezuclastinib in non-advanced systemic mastocytosis (SM). The treatment achieved significant...
KalVista’s oral drug wins FDA approval for hereditary angioedema after delay
After a delay attributed to FDA workload constraints, KalVista Pharmaceuticals received FDA approval for Ekterly (sebetralstat), the first oral on-demand treatment for hereditary angioedema (HAE)...
Concentra Biosciences extends buyout spree with Cargo Therapeutics acquisition
Serial biotech acquirer Concentra Biosciences, led by investor Kevin Tang, finalized a deal to acquire struggling cell therapy company Cargo Therapeutics. Cargo had faced significant challenges...
Single-cell genomics expands rapidly with falling sequencing costs
Single-cell RNA sequencing technology continues to mature, enabling more detailed cellular atlases and multiomic analyses. The International Human Cell Atlas Consortium leads efforts with data...
Apogee Therapeutics reports strong Phase 2 efficacy for IL-13 antibody in eczema
Apogee Therapeutics presented positive Phase 2 results for its anti-IL-13 antibody APG777 in moderate-to-severe atopic dermatitis. The candidate demonstrated a 71% reduction in disease severity by...
AI and biotech converge for protein engineering innovations
Researchers have developed AiCE, an AI-informed strategy that integrates structural and evolutionary constraints for enhanced protein engineering efficiency. This approach accelerates protein...
Biopharma financings see steady activity despite year-over-year decline
Biopharma companies raised $28.74 billion across the first half of 2025, representing a 59% decline compared to the same period in 2024 but aligning with prior years such as 2022 and 2023. Monthly...
Research breakthroughs in RNA, gene therapy and protein degradation emerge
Recent studies showcase advancements across multiple biomedical fields: a Nature Microbiology study identified key amino acid changes enhancing the yellow fever vaccine's safety and efficacy;...
KalVista’s Oral Drug Ekterly Gains FDA Nod for Rare Swelling Disorder
KalVista Pharmaceuticals secured FDA approval for Ekterly, an oral treatment for hereditary angioedema (HAE) attacks in patients aged 12 and above. The drug, sebetralstat, offers a convenient...
Cogent Biosciences Advances Mastocytosis Therapy With Phase 2 and 3 Data
Cogent Biosciences reported positive Phase 2 and Phase 3 clinical trial results for bezuclastinib, a tyrosine kinase inhibitor targeting non-advanced systemic mastocytosis (SM). The drug...
Apogee Therapeutics Shows Promise With Long-Acting IL-13 Antibody in Eczema
Apogee Therapeutics announced compelling Phase 2 data for APG777, its anti-IL-13 antibody targeting atopic dermatitis. The drug significantly reduced disease severity versus placebo and...
BostonGene and SWOG Launch Precision Trial Targeting Small Cell Lung Cancer
BostonGene and the SWOG Cancer Research Network initiated the S2409 PRISM Phase 2 clinical trial for extensive-stage small cell lung cancer (ES-SCLC). Utilizing BostonGene's machine...
Concentra Biosciences Accelerates Biotech Acquisitions With Cargo Therapeutics Buy
Concentra Biosciences, a serial acquirer of struggling biotech firms, has finalized the acquisition of Cargo Therapeutics amid the latter's financial distress and clinical setbacks. The deal...
AI Enables Discovery of Sperm Cells in 'Sterile' Samples, Leading to Pregnancy
Columbia University researchers adapted astrophysics-based AI algorithms to detect sperm cells missed by manual techniques in samples previously deemed sterile. The system, STAR, scanned millions...